609 fundamentals
ABIONYX PHARMA SA financial statements, including revenue, expenses, profit, and loss
The total revenue of 609 for the last semiannual is 2.34 M EUR, and it's 6.69% lower compared to the previous semiannual. The net income of H1 24 is -2.09 M EUR.
0.00
Total revenue
Gross profit
Operating income
Pretax income
Net income
Currency: EUR
TTM